新生儿播散性HAdV感染治疗方式的演变
本文报告一例经血液和支气管肺泡灌洗液宏基因组二代测序确诊的新生儿HAdV-D37感染病例,表现为发热和呼吸窘迫,接受静脉注射免疫球蛋白、甲泼尼龙和抗凝治疗并康复。对41例HAdV病例的回顾发现,静脉注射免疫球蛋白可能改善HAdV-D感染结局,糖皮质激素在重症或播散性疾病中可能有额外治疗价值,并建议监测凝血功能并及时抗凝以预防DIC相关并发症。
要点
- 新生儿HAdV感染罕见但常累及多器官且死亡率高
- mNGS可用于血液和BALF确诊新生儿HAdV感染
- IVIG可能改善HAdV-D感染结局,重症可考虑糖皮质激素
核心结论
- 静脉注射免疫球蛋白可能改善HAdV-D感染结局。
- 糖皮质激素在重症或播散性疾病中可能有额外治疗价值。
- 监测凝血功能并及时抗凝应考虑用于预防DIC相关并发症。
研究设计与样本
- 本文报告一例新生儿HAdV-D37感染病例,并通过血液和支气管肺泡灌洗液宏基因组二代测序确诊。
- 对41例HAdV病例进行回顾分析。
主要发现
- 病例表现为发热和呼吸窘迫,接受静脉注射免疫球蛋白、甲泼尼龙和抗凝治疗并康复。
- 41例HAdV病例回顾发现静脉注射免疫球蛋白可能改善HAdV-D感染结局。
临床怎么用
- 对疑似新生儿HAdV感染可采用血液和BALF的mNGS协助确诊。
- 重症或播散性HAdV感染可考虑IVIG联合糖皮质激素并监测凝血功能、及时抗凝。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Human adenovirus (HAdV) infection in newborns is a rare condition that typically affects multiple organ systems and has a high mortality rate. We report a case of neonatal HAdV-D37 infection that presented with fever and respiratory distress that was confirmed by metagenomic next-generation sequencing using blood and bronchoalveolar lavage fluid. We treated the patient with intravenous immunoglobulin, methylprednisolone, and anticoagulants, and the patient recovered. Our review of 41 cases of HAdV found that treatment with intravenous immunoglobin might have improved the outcome of HAdV-D infection. We further suggest that glucocorticoid therapy may have additional therapeutic validity in the setting of severe or disseminated disease and that monitoring coagulation function and timely anticoagulation treatment should be considered to prevent complications associated with disseminated intravascular coagulation.
引用
- Zhang W, Liu F, Liang E, et al. Evolution of Treatment Modalities for Disseminated HAdV Infection in Neonates. Pediatrics. 2024. PMID: 39238444. doi:10.1542/peds.2024-066677
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。